Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era

Basit Öğe Kaydı
dc.contributor.authorYersal, Ozlem
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorAliustaoglu, Mehmet
dc.contributor.authorBarutca, Sabri
dc.contributor.authorErdogdu, Halil Ibrahim
dc.date.accessioned2024-04-24T17:21:00Z
dc.date.available2024-04-24T17:21:00Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractNodal (N) status and molecular subtypes are well-known prognostic factors for breast cancer patients. The aim of the present study was to evaluate whether there was a prognostic role of molecular subtypes for pN3a breast cancer patients in the inodern therapeutic era. The present study retrospectively evaluated a total of 521 breast cancer patients who had 10 or more metastatic lymph nodes and received adjuvant systemic therapy at the Oncology Department of four different centers in Turkey between 2000-2015. Patients were divided into four molecular subtypes by immunohistochemical staining. There were no significant differences in relapse rates according to the molecular subtypes (P=0.07). The five year disease free survival rate was 62% for the whole study population, 67% for Luminal A tumors, 53% for Luminal B tumors, 64% for human epidermal growth factor receptor 2-positive tumors and 56% for triple negative tumors. Luminal A patients had a better progression free survival when compared with Luminal B (P=0.026) and triple negative (P=0.07) patients. pT stage (P<0.001), and breast cancer subtype (P<0.001), remained significant independent factors for disease free survival. Therefore, breast cancer subtypes are still prognostic for patients with pN3 breast cancer.en_US
dc.identifier.doi10.3892/mco.2018.1771
dc.identifier.endpage184en_US
dc.identifier.issn2049-9450
dc.identifier.issn2049-9469
dc.identifier.issue1en_US
dc.identifier.pmid30655995en_US
dc.identifier.startpage180en_US
dc.identifier.urihttps://doi.org/10.3892/mco.2018.1771
dc.identifier.urihttps://hdl.handle.net/11468/19335
dc.identifier.volume10en_US
dc.identifier.wosWOS:000454844500027
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpandidos Publ Ltden_US
dc.relation.ispartofMolecular and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectBiologyen_US
dc.subjectPrognosisen_US
dc.titleMolecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic eraen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu